华蟾素片、爱必妥注射液联合化疗治疗中晚期NSCLC的疗效  

Effect of Cinobufacini tablets, Erbitux Injection Combined with Chemotherapy on Patients with Advanced Non-small Cell Lung Cancer

作　　者：肖奇 王晓杰[2] 谢明水 熊斌 徐葳 付伟 丁彦珍 

机构地区：[1]解放军第九二医院肿瘤科,福建南平353000 [2]福建医科大学教学医院福建省肿瘤医院内科,福建福州350014

出　　处：《医学临床研究》2017年第11期2095-2097,共3页Journal of Clinical Research

摘　　要：【目的】探讨华蟾素片、爱必妥注射液联合化疗治疗中晚期非小细胞肺癌（NSCLC）患者的临床疗效及对存活质量的影响。【方法】将73例中晚期NSCLC患者随机分为两组，对照组采取TP（紫杉醇＋顺铂）方案化疗，观察组在对照组基础上加以华蟾素片、爱必要注射液治疗，比较两组近期疗效、不良反应、治疗前后相关情况变化。【结果】观察组总有效率为59．46％（22／37），显著高于对照组的33．33％（12／36）（P〈0．05），而两组疾病控制率相比较差异无显著性（P〉0．05）；观察组治疗后血清白介素-6（IL-6）、IL-10、CA125、癌胚抗原（CEA）、血管内皮生长因子（VEGF）水平均显著低于，IL-17、肿瘤坏死因子-α（TNF-α）水平显著高于对照组（P〈0．05）；观察组存活质量改善率为48．65％（18／37）显著高于对照组的25．00％（9／36）（P〈0．05）；观察组恶心呕吐、白细胞减少、贫血总发生率均低于对照组（P〈0．05）。【结论】华蟾素片、爱必妥注射液联合TP化疗能有效提高中晚期NSCLC患者近期疗效，增强其免疫功能，显著改善其存活质量，减少不良反应。[Objective] to investigate the clinical efficacy and quality of life of patients with advanced non small cell lung cancer （NSCLC） treated with Cinobufacini tablets and Erbitux injection combined TP chemotherapy .[Methods] Seventy-three cases of patients with advanced NSCLC were divided into the observation group（group A） and the control group（group 13）. The group B was treated with TP （paclitaxel and cisplatin） chemotherapy, and the group A was treated with einobufacini tablets and Erbitux injection on the basis of treatment in the group B. The short-term efficacy, adverse reactions, and related changes before and after treatment were compared between the two groups. [ResultslThe total effective rate of the observation group was 59.46% （22/37）, which was significantly higher than 33.33% （12/36） of the control group （ P 〈0.05）, but there was no significant difference in the disease control rate between the two groups （ P ）0.05）;the levels of serum interleukin-6 （IL-6）, IL-10, CA125, carcinoembryonic antigen （CEA） and vascular endothelial growth factor （VEGF） in the observation group were significantly lower than those in the observation group after treatment; IL 17, TNF-a level was significantly higher than that of the control group, and the difference was significant （ P 〈0.05）; the improvement rate of survival quality in the observation group was 48.65% （18/87）, which was significantly higher than 25% （9/56） in the control group （P 〈 0.05）; the incidence of nausea and vomiting, white blood cell reduction and anemia in the observation group were lower than those in the control group （ P 〈0.05）.[Conclusion] Cinobufacini tablets, Erbitux injection combined with TP chemotherapy can effectively improve the short-term efficacy, regulate immune abnormalities, enhance immune function, and significantly improve the quality of life in patients with advanced NSCLC. EKey words] CINOBUFAGIN/AD; TABLETS△ ; Antibodies, Monoclonal/AD; INJECTIO; Drug T

关 键 词：华蟾蜍毒素/投药和剂量 片剂 抗体 单克隆/投药和剂量 注射剂 药物疗法 联合 癌 非小细胞肺/药物疗法 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]